将 CAR T 细胞疗法试验带给服务不足的人群。
Bringing CAR T cell therapy trials to underserved populations.
机构信息
Dan L Duncan Comprehensive Cancer Center, Houston, TX, USA; Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Dan L Duncan Comprehensive Cancer Center, Houston, TX, USA; Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
出版信息
Cancer Cell. 2023 Dec 11;41(12):2007-2010. doi: 10.1016/j.ccell.2023.10.002. Epub 2023 Oct 26.
Abstract
There is a critical need for equitable access to cell therapies in cancer treatment, particularly within public safety-net healthcare systems that serve minority and socioeconomically disadvantaged populations. We discuss how the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine is piloting a cell therapy program aimed at addressing cancer care disparities and has the potential to serve as a national model for enhancing health equity in cancer care.
摘要
在癌症治疗中，特别是在为少数族裔和社会经济弱势群体服务的公共安全网医疗保健系统中，公平获得细胞疗法的需求至关重要。我们讨论了贝勒医学院丹·L·邓肯综合癌症中心如何试点细胞治疗计划，旨在解决癌症护理差距问题，并有可能成为提高癌症护理公平性的全国性模式。
相似文献
1
Bringing CAR T cell therapy trials to underserved populations.将 CAR T 细胞疗法试验带给服务不足的人群。
Cancer Cell. 2023 Dec 11;41(12):2007-2010. doi: 10.1016/j.ccell.2023.10.002. Epub 2023 Oct 26.
2
Medical School Outcomes, Primary Care Specialty Choice, and Practice in Medically Underserved Areas by Physician Alumni of MEDPREP, a Postbaccalaureate Premedical Program for Underrepresented and Disadvantaged Students.MEDPREP（一个面向代表性不足和处境不利学生的本科后医学预科项目）的医生校友的医学院校学习成果、初级保健专业选择以及在医疗服务不足地区的执业情况。
Teach Learn Med. 2017 Jul-Sep;29(3):351-359. doi: 10.1080/10401334.2016.1275970. Epub 2017 Mar 2.
3
Outcomes Among Minority Patients With Metastatic Colorectal Cancer in a Safety-net Health Care System.安全网医疗体系中转移性结直肠癌少数民族患者的结局。
Clin Colorectal Cancer. 2020 Jun;19(2):e49-e57. doi: 10.1016/j.clcc.2019.09.002. Epub 2020 Jan 2.
4
Evaluation of the Program in Medical Education for the Urban Underserved (PRIME-US) at the UC Berkeley-UCSF Joint Medical Program (JMP): The First 4 Years.加州大学伯克利分校-加州大学旧金山分校联合医学项目（JMP）中面向城市弱势群体的医学教育项目（PRIME-US）评估：头四年
Teach Learn Med. 2015;27(2):189-96. doi: 10.1080/10401334.2015.1011650.
5
The excess burden of breast carcinoma in minority and medically underserved communities: application, research, and redressing institutional racism.少数族裔及医疗服务不足社区中乳腺癌的额外负担：应用、研究与纠正制度性种族主义
Cancer. 2000 Mar 1;88(5 Suppl):1217-23. doi: 10.1002/(sici)1097-0142(20000301)88:5+<1217::aid-cncr7>3.0.co;2-k.
6
Access to CAR T-cell therapy: Focus on diversity, equity and inclusion.CAR T 细胞治疗的可及性：关注多样性、公平性和包容性。
Blood Rev. 2024 Jan;63:101136. doi: 10.1016/j.blre.2023.101136. Epub 2023 Oct 5.
7
Minority physicians' role in the care of underserved patients: diversifying the physician workforce may be key in addressing health disparities.少数族裔医生在为医疗服务不足患者提供护理方面的作用：使医生劳动力多元化可能是解决健康差距问题的关键。
JAMA Intern Med. 2014 Feb 1;174(2):289-91. doi: 10.1001/jamainternmed.2013.12756.
8
Nickel-and-Dimed in America: underserved, understudied, and underestimated.在美国身无分文：未得到充分服务、研究不足且被低估。
Fam Community Health. 2007 Jan-Mar;30(1 Suppl):S4-14. doi: 10.1097/00003727-200701001-00003.
9
Equity-Driven Approaches to Optimizing Cancer Care Coordination and Reducing Care Delivery Disparities in Underserved Patient Populations in the United States.以公平为导向的方法，用于优化美国医疗服务不足患者群体的癌症护理协调并减少护理提供差异。
JCO Oncol Pract. 2021 May;17(5):215-218. doi: 10.1200/OP.20.00895. Epub 2021 Apr 9.
10
A Review of Underserved and Vulnerable Populations in Headache Medicine in the United States: Challenges and Opportunities.美国头痛医学中服务不足和弱势人群的综述：挑战与机遇。
Curr Pain Headache Rep. 2022 Jun;26(6):415-422. doi: 10.1007/s11916-022-01042-w. Epub 2022 Mar 26.
引用本文的文献
1
Clinical outcomes of patients with newly diagnosed large B-cell lymphoma in a safety-net hospital system.安全网医院系统中初诊大B细胞淋巴瘤患者的临床结局
Blood Neoplasia. 2024 May 20;1(3):100020. doi: 10.1016/j.bneo.2024.100020. eCollection 2024 Sep.
2
How to democratize cell and gene therapy: A global approach.如何使细胞和基因疗法民主化：一种全球方法。
Mol Ther. 2025 May 7;33(5):2082-2090. doi: 10.1016/j.ymthe.2025.03.061. Epub 2025 Apr 2.
本文引用的文献
1
Medicaid coverage practices for approved gene and cell therapies: Existing barriers and proposed policy solutions.医疗补助计划对获批基因和细胞疗法的覆盖实践：现存障碍与政策解决方案建议
Mol Ther Methods Clin Dev. 2023 May 16;29:513-521. doi: 10.1016/j.omtm.2023.05.015. eCollection 2023 Jun 8.
2
Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice.嵌合抗原受体 T 细胞（CAR-T）疗法在临床实践中的障碍。
Pharmaceut Med. 2022 Jun;36(3):163-171. doi: 10.1007/s40290-022-00428-w. Epub 2022 Jun 7.
3
Process, resource and success factors associated with chimeric antigen receptor T-cell therapy for multiple myeloma.与嵌合抗原受体T细胞疗法治疗多发性骨髓瘤相关的过程、资源和成功因素。
Future Oncol. 2022 Jun;18(19):2415-2431. doi: 10.2217/fon-2022-0162. Epub 2022 May 18.
4
Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms.支持美国食品和药物管理局批准嵌合抗原受体 T 细胞疗法治疗血液恶性肿瘤的关键临床试验中纳入黑人参试者的情况。
JAMA Netw Open. 2022 Apr 1;5(4):e228161. doi: 10.1001/jamanetworkopen.2022.8161.
5
Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access.嵌合抗原受体 T 细胞疗法可及性的社会经济和种族差异。
Transplant Cell Ther. 2022 Jul;28(7):358-364. doi: 10.1016/j.jtct.2022.04.008. Epub 2022 Apr 13.
6
Multiple Myeloma in Hispanics: Incidence, Characteristics, Survival, Results of Discovery, and Validation Using Real-World and Connect MM Registry Data.西班牙语裔人群中的多发性骨髓瘤：发病情况、特征、生存情况、应用真实世界和 Connect MM 登记数据的发现结果和验证。
Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):e384-e397. doi: 10.1016/j.clml.2020.11.013. Epub 2020 Nov 21.
7
Perceptions of community hematologists/oncologists on barriers to chimeric antigen receptor T-cell therapy for the treatment of diffuse large B-cell lymphoma.社区血液学家/肿瘤学家对嵌合抗原受体 T 细胞疗法治疗弥漫性大 B 细胞淋巴瘤的障碍的看法。
Immunotherapy. 2020 Jul;12(10):725-732. doi: 10.2217/imt-2020-0118. Epub 2020 Jun 18.
8
Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018.2008年至2018年导致癌症药物获批的临床试验中种族报告与代表性的差异
JAMA Oncol. 2019 Oct 1;5(10):e191870. doi: 10.1001/jamaoncol.2019.1870. Epub 2019 Oct 10.
9
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.Tisagenlecleucel 治疗成人复发或难治性弥漫性大 B 细胞淋巴瘤。
N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.
10
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.阿基仑赛注射液嵌合抗原受体T细胞疗法治疗难治性大B细胞淋巴瘤
N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10.
Zotero 插件